MiR-29a: a potential therapeutic target and promising biomarker in tumors

Biosci Rep. 2018 Feb 8;38(1):BSR20171265. doi: 10.1042/BSR20171265. Print 2018 Feb 28.

Abstract

MiRNAs, small non-coding RNA molecules, were recognized to be associated with the incidence and development of diverse neoplasms. MiRNAs were small non-coding RNAs that could regulate post-transcriptional level by binding to 3'-UTR of target mRNAs. Amongst which, miR-29a was demonstrated that it had significant impact on oncogenicity in various neoplasms through binding to critical genes which enhanced or inhibited the progression of cancers. MiR-29a participated in kinds of physiological and pathological processes, including virus replication, cell proliferation, differentiation, apoptosis, fibrosis, angiogenesis, tumorigenicity, metastasis, drug-resistance, and so on. According to its sufficient sensitivity and specificity, many studies showed that miR-29a might serve as a potential therapeutic target and promising biomarker in various tumors. In this review, we discussed the functions of miR-29a and its potential application in the diagnosis, treatment and stages of carcinoma, which could provide additional insight to develop a novel therapeutic strategy.

Keywords: biomarkers; cancer; metastases; miR-29a; microRNA; proliferation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Apoptosis / genetics
  • Biomarkers, Tumor / genetics*
  • Cell Proliferation / genetics
  • Humans
  • MicroRNAs / genetics*
  • Molecular Targeted Therapy*
  • Neoplasms / drug therapy
  • Neoplasms / genetics*
  • Neoplasms / pathology

Substances

  • Biomarkers, Tumor
  • MIRN29a microRNA, human
  • MicroRNAs